Document Detail


Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.
MedLine Citation:
PMID:  19959243     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Most schizophrenic patients have a deficit in auditory sensory gating that appears to be mediated by the alpha-7 nicotinic receptor. This pilot study examines the effects of varenicline, an alpha-7 agonist, on the P50 auditory evoked potential in six schizophrenic patients. The study was canceled because of concerning side effects consistent with those reported by the FDA. However, in this small group of subjects, varenicline did not consistently enhance P50 auditory gating.
Authors:
Merilyne C Waldo; Laurie Woodward; Lawrence E Adler
Related Documents :
12928513 - The frontal lobe neuropsychological tests in patients with schizophrenia and/or obsessi...
7030443 - Propranolol in schizophrenia. ii. clinical and biochemical aspects of combining propran...
12967063 - The beneficial effect of donepezil on visual hallucinations in three patients with park...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-12-02
Journal Detail:
Title:  Psychiatry research     Volume:  175     ISSN:  0165-1781     ISO Abbreviation:  Psychiatry Res     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-02-01     Completed Date:  2010-03-16     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  7911385     Medline TA:  Psychiatry Res     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  179-80     Citation Subset:  IM    
Affiliation:
The Denver VAMC VISN19/MIRECC and UC Denver, School of Medicine, Department of Psychiatry, CO 80220, USA. merilyne.waldo@va.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acoustic Stimulation / methods
Analysis of Variance
Benzazepines / pharmacology*,  therapeutic use
Double-Blind Method
Evoked Potentials, Auditory / drug effects*
Humans
Nicotinic Agonists / pharmacology*,  therapeutic use
Pilot Projects
Quinoxalines / pharmacology*,  therapeutic use
Reaction Time / drug effects
Schizophrenia / drug therapy,  physiopathology*
Sensory Gating / drug effects*
Statistics, Nonparametric
Grant Support
ID/Acronym/Agency:
R01 MH050787-12/MH/NIMH NIH HHS; R01 MH50787-08/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Benzazepines; 0/Nicotinic Agonists; 0/Quinoxalines; W6HS99O8ZO/varenicline
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neurological soft signs and schizotypal dimensions in unaffected siblings of patients with schizophr...
Next Document:  Protective effect of glutathione S-transferase-fused mutant staphylococcal enterotoxin C against Sta...